Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration

Advances in Therapy

Volumn 33, Issue 3, 2016, Pages 369-378

  Bianchi, Gerolamo ^a   Caporali, Roberto ^b   Todoerti, Monica ^b   Mattana, Paolo ^c  

^a Division of Rheumatology   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Alfa Wassermann SpA   (Italy)

Author keywords

Methotrexate; Oral route; Rheumatoid arthritis; Rheumatology; Subcutaneous route

Indexed keywords

METHOTREXATE; ANTIRHEUMATIC AGENT;

BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COST CONTROL; DAS28; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; DOSE RESPONSE; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, SUBCUTANEOUS; METHOTREXATE;

EID: 84957582274     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-016-0295-8     Document Type: Review

References (23)

1. Bijlsma JW, Jacobs JW. Methotrexate: still the anchor drug in RA treatment. Jt Bone Spine. 2009;76(5):452–4.
2. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;6:CD000957.
3. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625–39.
4. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75.
5. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897–904.
6. Mouterde G, Baillet A, Gaujoux-Viala C, et al. Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. Jt Bone Spine. 2011;78(6):587–92.
7. Todoerti M, Maglione W, Bernero E, et al. Systematic review of 2008–2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis. Reumatismo. 2013;65(5):207–18.
8. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66(11):1443–9.
9. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. Clin Ther. 2014;36(3):427–35.
10. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–9.
11. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20(11):1845–9.
12. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645–8.
13. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73(8):1549–51.
14. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73–81.
15. Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis. 2010;69(10):1849–52.
16. Mainman H, McClaren E, Heycock C, Saravanan V, Hamilton J, Kelly C. When should we use parenteral methotrexate? Clin Rheumatol. 2010;29(10):1093–8.
17. Scott DG, Claydon P, Ellis C. Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study. Scand J Rheumatol. 2014;43(6):470–6.
18. Rutkowska-Sak L, Rell-Bakalarska M, Lisowska B. Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. Reumatologia. 2009;47(7):207–11.
19. Muller RB, von Kempis J, Haile SR, Schiff MH. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum. 2015;45(1):28–34.
20. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
21. Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2015. pii: annrheumdis-2014-206504. doi:10.1136/annrheumdis-2014-206504[Epub ahead of print].
22. De Leonardis F, Alivernini S, Bonacci E, et al. Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the “3E initiative”. Reumatismo. 2010;62(1):34–45.
23. Fitzpatrick R, Scott DG, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32(11):1605–12.